Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks
ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance
Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin ® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year ...
Barchart Research What to Expect from ANIP Earnings ANIP Generated August 6, 2026 Current Price $82.63 EPS Estimate $$1.67 Consensus Rating Strong Buy Average Move 7.23% ANI Pharmaceuticals Reports Tomorrow...
ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect
1 Healthcare Stock Worth Your Attention and 2 We Question
PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results...
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds